Võrdle meetodeid

	Risk-adjusted Phase IV study	Kalduvusskoori sobitamine
Valdkond	Epidemioloogia	Uurimisstatistika
Perekond	Process / pipeline	Process / pipeline
Tekkeaasta	1990s–2000s (formalized with ICH E2E and EMA PASS guidelines)	1983
Looja	Regulatory and pharmacoepidemiology community (ICH, EMA, FDA frameworks)	Paul Rosenbaum and Donald Rubin
Tüüp	Observational / quasi-experimental clinical study design	Method
Algallikas	Strom, B. L. (Ed.). (2005). Pharmacoepidemiology (4th ed.). John Wiley & Sons. ISBN: 978-0470863107	Rosenbaum, P. R., & Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1), 41–55.
Rööpnimetused	risk-adjusted post-marketing surveillance study, adjusted Phase IV trial, risk-stratified post-authorization study, PASS with risk adjustment	PSM, propensity score weighting, covariate balance
Seotud	3	3
Kokkuvõte	A risk-adjusted Phase IV study is an observational or semi-experimental post-marketing study conducted after a drug or device has received regulatory approval. It uses statistical risk-adjustment techniques — such as propensity score matching, inverse probability weighting, or multivariable regression — to control for confounding by indication and baseline patient differences, thereby producing more credible safety, effectiveness, and utilization estimates than unadjusted real-world analyses.	Propensity score matching (PSM) is a method for reducing confounding bias in observational studies by balancing baseline characteristics between treatment groups, simulating randomization. Developed by Rosenbaum and Rubin (1983), it estimates the probability of receiving treatment given observed covariates, then matches or weights treated and control individuals with similar treatment probabilities. Widely used in medicine, epidemiology, and policy evaluation when randomized trials are infeasible or unethical, enabling estimation of treatment effects while controlling for selection bias.